May 2004
Volume 45, Issue 13
ARVO Annual Meeting Abstract  |   May 2004
Survey of 1264 Patients with Orbital Tumors and Simulating Lesions
Author Affiliations & Notes
  • R. Scartozzi
    Oncology, Wills Eye Hospital, Philadelphia, PA
  • J.A. Shields
    Oncology, Wills Eye Hospital, Philadelphia, PA
  • C.L. Shields
    Oncology, Wills Eye Hospital, Philadelphia, PA
  • Footnotes
    Commercial Relationships  R. Scartozzi, None; J.A. Shields, None; C.L. Shields, None.
  • Footnotes
    Support  Eye Tumor Research Foundation; Award of Merit in Retina Research; Macula Foundation
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 4693. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      R. Scartozzi, J.A. Shields, C.L. Shields; Survey of 1264 Patients with Orbital Tumors and Simulating Lesions . Invest. Ophthalmol. Vis. Sci. 2004;45(13):4693.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: To determine the incidence of specific orbital tumors based on a large clinical series of patients referred to an ocular oncology center. Methods: A retrospective chart review was done on 1264 consecutive patients referred for a suspected orbital mass over a 30–year period. The lesions were grouped into several categories (see Results section). The specific diagnosis in each case was based on clinical findings, computed tomography, magnetic resonance imaging, and histopathology when available. The number and percent of benign and malignant tumors per age group were also determined. Results: Among 1264 consecutive patients, the number and percent of lesions in each category were as follows: 70 cystic (6%), 213 vasculogenic (17%), 23 peripheral nerve (2%), 105 optic nerve and meningeal (8%), 13 fibrocytic (1%), 21 osseous/fibro–osseous (2%), 1 cartilagenous (<1%), 64 lipocytic/myxoid (5%), 36 myogenic (3%), 114 lacrimal gland (9%), 11 melanocytic (1%), 91 metastatic (7%), 130 lymphoma/leukemia (10%), 142 secondary (11%), 17 histiocytic (1%), 67 thyroid–related orbitopathy (5%), 133 inflammatory lesions (11%), and 13 miscellaneous lesions (1%). The most common specific diagnoses were lymphoid tumor (139 cases; 11%), idiopathic orbital inflammation (135 cases; 11%), cavernous hemangioma (77 cases; 6%), lymphangioma (54 cases; 4%), meningioma (53 cases; 4%), optic nerve glioma (48 cases; 4%), metastatic breast cancer (44 cases; 4%), rhabdomyosarcoma (35 cases; 3%), dermolipoma (31 cases; 3%), herniated orbital fat (30 cases; 2%), dermoid cyst (26 cases; 2%), varix (26 cases; 2%), dacryops (19 cases; 2%). Of the 1264 lesions, 810 (64%) were benign and 454 (36%) were malignant. Of the malignant lesions, 20% occurred in patients 0–18 years of age, 27% in those 19–59 years of age, and 58% in those 60–92 years of age. Rhabdomyosarcoma was the most common specific malignancy in younger patients while lymphoma was the most common malignancy in older patients. Conclusions: A variety of tumors and pseudotumors can involve the orbit. In this series of 1264 lesions, 64% were benign and 36% were malignant. The percent of malignant tumors increased with age due to the higher incidence of lymphomas, secondary, and metastatic lesions in the elderly. It is hoped that the large number of patients in this study will accurately reflect the incidence of the various space–occupying orbital lesions that may prompt an ophthalmologist to refer to an ocular oncology specialist, thus aiding in the construction of a differential diagnosis for the referring physician.

Keywords: oncology • orbit • tumors 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.